Last 12 months
Inside the activity.
2 purchase rows · 30 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2022 Filed May 22, 2023 19:45 UTC |
Dahut Karen MDirector
|
GiftCommon Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-23-000134 · edgardoc.xml · nonDerivative · entry 4 Dahut Karen M · CIK 0001533450 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 6,768 F1 · shares: Shares were transferred from direct ownership to ownership under the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, upon vesting of previously awarded restricted stock units. Read SEC document |
| August 11, 2022 Filed May 22, 2023 19:45 UTC |
Dahut Karen MDirector
|
GiftCommon Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-23-000134 · edgardoc.xml · nonDerivative · entry 1 Dahut Karen M · CIK 0001533450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,492 F1 · shares: Shares were transferred from direct ownership to ownership under the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, upon vesting of previously awarded restricted stock units. Read SEC document |
| July 25, 2022 Filed Jul 25, 2022 22:00 UTC |
Pacelli Steven RobertEVP Managing Director Dexcom V
|
SaleCommon Stock | 1,000 | $83.07 | $83,070.00 |
DisclosureSEC source: 0001093557-22-000132 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,700 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:46 UTC |
Pacelli Steven RobertEVP Managing Director Dexcom V
|
SaleCommon Stock | 1,000 | $72.55 | $72,550.00 |
DisclosureSEC source: 0001093557-22-000130 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,700 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 45,820 unvested restricted stock units, 19,936 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 14,136 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| June 06, 2022 Filed Jun 6, 2022 20:52 UTC |
Sylvain Jereme MEVP Chief Financial Officer
|
SaleCommon Stock | 600 | $301.57 | $180,942.00 |
DisclosureSEC source: 0001093557-22-000128 · edgardoc.xml · nonDerivative · entry 1 Sylvain Jereme M · CIK 0001681267 · EVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,408 F1 · shares: On June 4, 2021, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:44 UTC |
Pacelli Steven RobertEVP Managing Director Dexcom V
|
SaleCommon Stock | 250 | $296.33 | $74,082.50 |
DisclosureSEC source: 0001093557-22-000124 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Managing Director Dexcom V 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,175 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:08 UTC |
TOPOL ERICDirector
|
GrantCommon Stock | 988 | $0.00 | $0.99 |
DisclosureSEC source: 0001093557-22-000122 · edgardoc.xml · nonDerivative · entry 2 TOPOL ERIC · CIK 0001468345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 988 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 988 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:07 UTC |
SKYLER JAY SDirector
|
GrantCommon Stock | 969 | $0.00 | $0.97 |
DisclosureSEC source: 0001093557-22-000121 · edgardoc.xml · nonDerivative · entry 2 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 969 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:06 UTC |
Malady KyleDirector
|
GrantCommon Stock | 979 | $0.00 | $0.98 |
DisclosureSEC source: 0001093557-22-000120 · edgardoc.xml · nonDerivative · entry 1 Malady Kyle · CIK 0001760581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,161 F1 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2 · balance_after: Included in this number are 1,827 unvested restricted stock units, 979 of which were granted on May 20, 2022 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2023 Annual Meeting and 848 of which were granted on October 11, 2020 and shall vest through October 11, 2023. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:06 UTC |
KAHN BARBARADirector
|
GrantCommon Stock | 994 | $0.00 | $0.99 |
DisclosureSEC source: 0001093557-22-000119 · edgardoc.xml · nonDerivative · entry 2 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 994 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:05 UTC |
Heller Bridgette PDirector
|
GrantCommon Stock | 988 | $0.00 | $0.99 |
DisclosureSEC source: 0001093557-22-000118 · edgardoc.xml · nonDerivative · entry 1 Heller Bridgette P · CIK 0001485616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,355 F1 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F2 · balance_after: Included in this number are 2,000 unvested restricted stock units, 988 of which were granted on May 20, 2022 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2023 Annual Meeting and 1,012 of which were granted on September 13, 2019 and shall vest through September 13, 2022. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:05 UTC |
FOLETTA MARK GDirector
|
GrantCommon Stock | 1,122 | $0.00 | $1.12 |
DisclosureSEC source: 0001093557-22-000117 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 1,122 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:04 UTC |
Dahut Karen MDirector
|
GrantCommon Stock | 987 | $0.00 | $0.99 |
DisclosureSEC source: 0001093557-22-000116 · edgardoc.xml · nonDerivative · entry 3 Dahut Karen M · CIK 0001533450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,760 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Included in this number are 1,760 unvested restricted stock units, 987 of which were granted on May 20, 2022 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2023 Annual Meeting and 773 of which were granted on August 11, 2020 and shall vest through August 11, 2023. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:04 UTC |
Collins Richard AlexanderDirector
|
GrantCommon Stock | 987 | $0.00 | $0.99 |
DisclosureSEC source: 0001093557-22-000115 · edgardoc.xml · nonDerivative · entry 2 Collins Richard Alexander · CIK 0001700619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 987 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:04 UTC |
AUGUSTINOS NICHOLASDirector
|
GrantCommon Stock | 994 | $0.00 | $0.99 |
DisclosureSEC source: 0001093557-22-000114 · edgardoc.xml · nonDerivative · entry 2 AUGUSTINOS NICHOLAS · CIK 0001238485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 994 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:03 UTC |
ALTMAN STEVEN RDirector
|
GrantCommon Stock | 979 | $0.00 | $0.98 |
DisclosureSEC source: 0001093557-22-000113 · edgardoc.xml · nonDerivative · entry 2 ALTMAN STEVEN R · CIK 0001191307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 979 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:08 UTC |
TOPOL ERICDirector
|
OtherCommon Stock | 919 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000122 · edgardoc.xml · nonDerivative · entry 3 TOPOL ERIC · CIK 0001468345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Holdings Disclosed balance after: 92,766 F1 · shares: Shares were transferred from direct ownership to ownership under the Topol Family Holdings, LLC, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by Topol Family Holdings, LLC, with respect to which the reporting person is a manager and maintains voting rights of these shares. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:08 UTC |
TOPOL ERICDirector
|
OtherCommon Stock | 919 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000122 · edgardoc.xml · nonDerivative · entry 1 TOPOL ERIC · CIK 0001468345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Topol Family Holdings, LLC, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:07 UTC |
SKYLER JAY SDirector
|
OtherCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000121 · edgardoc.xml · nonDerivative · entry 3 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 14,868 F1 · shares: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:07 UTC |
SKYLER JAY SDirector
|
OtherCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000121 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:06 UTC |
KAHN BARBARADirector
|
OtherCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000119 · edgardoc.xml · nonDerivative · entry 3 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,918 F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:06 UTC |
KAHN BARBARADirector
|
OtherCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000119 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:05 UTC |
FOLETTA MARK GDirector
|
OtherCommon Stock | 1,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000117 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,651 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:05 UTC |
FOLETTA MARK GDirector
|
OtherCommon Stock | 1,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000117 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:04 UTC |
Dahut Karen MDirector
|
OtherCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000116 · edgardoc.xml · nonDerivative · entry 5 Dahut Karen M · CIK 0001533450 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,305 F1 · shares: Shares were transferred from direct ownership to ownership under the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, with respect to which the reporting person is a trustee. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:04 UTC |
Dahut Karen MDirector
|
OtherCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000116 · edgardoc.xml · nonDerivative · entry 2 Dahut Karen M · CIK 0001533450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773 F1 · shares: Shares were transferred from direct ownership to ownership under the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:04 UTC |
Collins Richard AlexanderDirector
|
OtherCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000115 · edgardoc.xml · nonDerivative · entry 3 Collins Richard Alexander · CIK 0001700619 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,114 F1 · shares: Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:04 UTC |
Collins Richard AlexanderDirector
|
OtherCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000115 · edgardoc.xml · nonDerivative · entry 1 Collins Richard Alexander · CIK 0001700619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:04 UTC |
AUGUSTINOS NICHOLASDirector
|
OtherCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000114 · edgardoc.xml · nonDerivative · entry 3 AUGUSTINOS NICHOLAS · CIK 0001238485 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,510 F1 · shares: Shares were transferred from direct ownership to ownership under the Kirschner/Augustinos Revocable Trust, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Kirschner/Augustinos Revocable Trust, of which the reporting person is trustee. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:04 UTC |
AUGUSTINOS NICHOLASDirector
|
OtherCommon Stock | 918 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000114 · edgardoc.xml · nonDerivative · entry 1 AUGUSTINOS NICHOLAS · CIK 0001238485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Kirschner/Augustinos Revocable Trust, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:03 UTC |
ALTMAN STEVEN RDirector
|
OtherCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000113 · edgardoc.xml · nonDerivative · entry 3 ALTMAN STEVEN R · CIK 0001191307 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,696 F1 · shares: Shares were transferred from direct ownership to ownership under the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee. Read SEC document |
| May 19, 2022 Filed May 23, 2022 21:03 UTC |
ALTMAN STEVEN RDirector
|
OtherCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-22-000113 · edgardoc.xml · nonDerivative · entry 1 ALTMAN STEVEN R · CIK 0001191307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 09, 2022 Filed May 10, 2022 20:11 UTC |
Patterson ChadEVP Global Marketing
|
SaleCommon Stock | 777 | $342.77 | $266,332.29 |
DisclosureSEC source: 0001093557-22-000102 · edgardoc.xml · nonDerivative · entry 1 Patterson Chad · CIK 0001850152 · EVP Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,675 F1 · shares: On June 14, 2021, Mr. Patterson adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Patterson. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,675 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:47 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 250 | $439.94 | $109,985.00 |
DisclosureSEC source: 0001093557-22-000092 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,425 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 20:43 UTC |
Patterson ChadEVP, Global Marketing
|
SaleCommon Stock | 776 | $498.75 | $387,030.00 |
DisclosureSEC source: 0001093557-22-000088 · edgardoc.xml · nonDerivative · entry 1 Patterson Chad · CIK 0001850152 · EVP, Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,452 F1 · shares: On June 14, 2021, Mr. Patterson adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Patterson. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 13,675 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 21:49 UTC |
Regan Barry J.EVP Global Operations
|
SaleCommon Stock | 1,106 | $500.00 | $553,000.00 |
DisclosureSEC source: 0001093557-22-000078 · edgardoc.xml · nonDerivative · entry 1 Regan Barry J. · CIK 0001746313 · EVP Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,345 F1 · shares: On September 14, 2021, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 16,345 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 20:35 UTC |
Pacelli Steven RobertManaging Dir., Dexcom Ventures
|
SaleCommon Stock | 250 | $459.98 | $114,995.00 |
DisclosureSEC source: 0001093557-22-000067 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · Managing Dir., Dexcom Ventures 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,675 F1 · shares: On June 14, 2021, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 11,455 unvested restricted stock units, 4,984 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 2,937 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 20:30 UTC |
Dolan Matthew VincentSVP Corporate Development
|
SaleCommon Stock | 484 | $450.00 | $217,800.00 |
DisclosureSEC source: 0001093557-22-000065 · edgardoc.xml · nonDerivative · entry 3 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,634 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:30 UTC |
Dolan Matthew VincentSVP Corporate Development
|
SaleCommon Stock | 686 | $425.00 | $291,550.00 |
DisclosureSEC source: 0001093557-22-000065 · edgardoc.xml · nonDerivative · entry 2 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,118 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:30 UTC |
Dolan Matthew VincentSVP Corporate Development
|
SaleCommon Stock | 1,016 | $412.41 | $419,008.56 |
DisclosureSEC source: 0001093557-22-000065 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,804 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 150 | $416.42 | $62,463.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 10 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,883 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $416.13 to $417.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 100 | $414.99 | $41,499.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,033 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 50 | $413.51 | $20,675.50 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,133 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $413.14 to $414.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 450 | $412.27 | $185,521.50 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,183 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $411.91 to $412.41. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 405 | $411.25 | $166,556.25 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,633 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $410.79 to $411.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 445 | $410.00 | $182,450.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,038 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $409.67 to $410.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 400 | $408.89 | $163,556.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,483 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $408.53 to $409.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 150 | $407.60 | $61,140.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,883 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $407.48 to $408.055. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 405 | $407.00 | $164,835.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,033 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $406.37 to $407.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC |
SAYER KEVIN RDirector · Chairman, CEO & President
|
SaleCommon Stock | 445 | $405.84 | $180,598.80 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,438 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $405.24 to $406.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.